TY - JOUR T1 - Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA3654 VL - 54 IS - suppl 63 SP - PA3654 AU - Clara Vigneron AU - Alexandre Vivot AU - Matthieu Jamme AU - Aude Gibelin AU - Guillaume Briend AU - Jean Pastré AU - Benjamin Planquette AU - Guy Meyer AU - Olivier Sanchez Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA3654.abstract N2 - Introduction: In randomized controlled trials, direct oral anticoagulants are at least as effective and probably safer than standard anticoagulation in patients with venous thromboembolism (VTE). Real-life studies are of particular interest for the assessment of their efficacy and safety in unselected patients.Methods: We conducted a retrospective analysis of a prospective monocentric cohort including patients with symptomatic pulmonary embolism (PE) treated with VKA or rivaroxaban (riva) with a 6-month follow-up. We distinguished 2 periods: P1 (2010-2013) when only VKA was available; P2 (2014-2017) when VKA and riva were available. The primary outcome was the composite of all-cause mortality, major or clinically significant bleeding and symptomatic recurrent VTE under treatment. Outcomes and length of stay (LOS) were compared between riva and VKA groups using a propensity score analysis.Results: 706 patients were analysed: 271 during P1, 435 during P2 (VKA: n=143, Riva: n=292).No difference in the primary outcome was observed between P1 and P2 (respectively 8,1% vs 4,8%, p=0.1045). LOS was significantly reduced during P2 (5 [3,7] vs 6 days [4,10], p<0.0001).During P2, compared to VKA, patients treated with riva were younger (65 [49,75] vs 71 years [53,82], p=0.0044) and the proportion of patients with comorbidities was lower. In the propensity score adjustment sample, the primary outcome (OR 2.91 [95%CI, 1.03-8.26], p=0.044) was significantly higher in the VKA group compared to the riva group. LOS was significantly reduced in the riva group (4 vs 7 days, p<0.0001).Conclusion: Riva appears to be effective and safe to treat PE in a non-selected population with a shorter LOS.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA3654.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -